知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

89 records (took 0.022 seconds)

    BICYCLIC PEPTIDE LIGAND SPECIFIC FOR CD137
    32.
    发明申请
    BICYCLIC PEPTIDE LIGAND SPECIFIC FOR CD137 审中-公开

    公开(公告)号：US20200255477A1

    公开(公告)日：2020-08-13

    申请号：US16636105

    申请日：2018-08-03

    Applicant: BicycleTx Limited

    Inventor： Liuhong Chen ,  Rachid Lani ,  Kevin McDonnell ,  Gemma Mudd ,  Peter Park

    IPC: C07K7/64 ,  A61K47/64

    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

    PEPTIDE LIGANDS FOR BINDING TO MT1-MMP
    37.
    发明公开
    PEPTIDE LIGANDS FOR BINDING TO MT1-MMP 审中-公开

    公开(公告)号：US20230340020A1

    公开(公告)日：2023-10-26

    申请号：US17946380

    申请日：2022-09-16

    Applicant: BicycleTX Limited

    Inventor： Daniel TEUFEL ,  Gemma MUDD ,  Silvia PAVAN

    IPC: C07K7/08 ,  A61K47/64 ,  G01N33/573

    CPC classification number: C07K7/08 ,  A61K47/64 ,  A61K47/6415 ,  G01N33/573

    Abstract: A peptide ligand specific for MT1-MMP comprising a polypeptide comprising two diaminopropionic acid (Dap) or N-alkyldiaminopropionic acid (N-AlkDap) residues, and a third residue selected from cysteine, Dap or N-AlkDap, separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap residues of the polypeptide and by covalent thioether linkages with the cysteine when the third residue is cysteine, such that two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence of formula (II): -A1-X1-U/O2-X3-X4-G5-A2-E6-D7-F8-Y9-X10-X11-A3- (SEQ ID NO: 1) (II) or a pharmaceutically acceptable salt thereof; wherein: A1, A2, and A3 are independently cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap), or N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), provided that at least one of A1, A2, and A3 is Dap, N-AlkDap or N-HAlkDap; X represents any amino acid residue; U represents a polar, uncharged amino acid residue selected from N, C, Q, M, S and T; and O represents a non-polar aliphatic amino acid residue selected from G, A, I, L, P and V.

    BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17
    38.
    发明申请
    BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 有权

    公开(公告)号：US20230039677A1

    公开(公告)日：2023-02-09

    申请号：US17782931

    申请日：2020-12-16

    Applicant: BicycleTx Limited

    Inventor： Paul BESWICK ,  Gemma MUDD

    IPC: C07K7/08 ,  A61K47/64

    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of IL-17. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by IL-17.

    Bicyclic peptide ligands specific for EphA2
    39.
    发明授权
    Bicyclic peptide ligands specific for EphA2 有权

    公开(公告)号：US11484602B2

    公开(公告)日：2022-11-01

    申请号：US16220685

    申请日：2018-12-14

    Applicant: BicycleTx Limited

    Inventor： Liuhong Chen ,  Philip Huxley ,  Silvia Pavan ,  Katerine Van Rietschoten

    IPC: A61K47/64 ,  A61P35/00 ,  A61K47/65 ,  A61K38/10 ,  A61K38/05 ,  A61K47/62 ,  C07K7/08

    Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

    BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN
    40.
    发明申请
    BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN 有权

    公开(公告)号：US20220339289A1

    公开(公告)日：2022-10-27

    申请号：US17659934

    申请日：2022-04-20

    Applicant: BicycleTx Limited

    Inventor： Kevin MCDONNELL ,  Gemma MUDD ,  Michael SKYNNER ,  Sophie WATCHAM

    IPC: A61K47/64 ,  C07K7/06 ,  C07K14/745

    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.

Patent Agency Ranking